Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Protein Losing Enteropathy
Interventions
DRUG

ODSH at 0.125 mg/kg/h

ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.

DRUG

ODSH at 0.375 mg/kg/h

ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.

DRUG

ODSH at 0.250 mg/kg/h

ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.

Trial Locations (4)

20027-6016

Children's Hospital Los Angeles ( Gastroenterology & Nutrition), Los Angeles

02115

Department of Cardiology, Children's Hospital Boston, Boston

48109-5204

Division of Pediatric Cardiology, University of Michigan Health System, Ann Arbor

57104-4707

Sanford Children's ( Sanford Research / USD), Sioux Falls

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY